More than two years after the beginning of the pandemic, the Ministry of Health will offer the SUS a drug indicated in the package insert against Covid-19.
The folder led by Marcelo Queiroga published this Friday (1st) the incorporation of treatment with barictinib to the public network for adult patients, hospitalized and who need oxygen by mask or nasal catheter.
Manufactured by the Lilly laboratory, the anti-inflammatory is primarily used in the treatment of rheumatoid arthritis.
Conitec (National Commission for the Incorporation of Technologies in the Unified Health System) recommended the incorporation of the product to the SUS on Wednesday (30).
The government has not yet released an estimate of how many patients should receive the product and what the price should be for purchasing the drug.
“The studies analyzed by the Commission point out that the use of the drug can contribute to a significant reduction of deaths from Covid-19 of hospitalized adult patients and who need oxygen by mask or nasal catheter, or who need high flow oxygen or non-invasive ventilation. invasive”, said Saúde, in a note.
A Conitec report cites an estimated cost of R$ 1.53 million in five years when offering the product. The value considers the reduction of expenses with other interventions and the purchase of the product, for example.
Today the first generation of drugs against Covid-19 is found only in the private network.
The Jair Bolsonaro government (PL) has already offered ineffective medicines for Covid-19 in the SUS, such as chloroquine and hydroxychloroquine. as showed the sheetthese drugs are now stored and unused.
Even so, the pro-chloroquine wing at the Ministry of Health mobilized to boycott the discussion about vetoing the use of the “Covid kit” in the public network.
Baricitinib is registered in Brazil for the treatment of rheumatoid arthritis and atopic dermatitis. In September 2021, Anvisa (National Health Surveillance Agency) approved the indication against Covid-19.
The product has already been recommended by the WHO (World Health Organization) in the treatment of Covid-19.
“More specifically, it reduces the action of interleukin-6 (IL-6), a substance linked to the occurrence of inflammatory reactions generated by various diseases and presents with high levels in more severe cases of the disease”, said Saúde.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
